VERTEX PHARMACEUTICALS INC (VRTX) Stock News
NASDAQ:VRTX - Nasdaq - US92532F1003 - Common Stock
VRTX Latest News and Analysis
Got $1,500? 3 Healthcare Stocks to Buy and Hold Forever
3 Unstoppable Stocks to Buy in 2025
3 Unstoppable Stocks to Buy in 2025
Three Motley Fool contributors believe they've identified healthcare stocks in the latter category. Here's why they think Eli Lilly (NYSE: LLY), Intuitive Surgical (NASDAQ: ISRG), and Vertex Pharmaceuticals (NASDAQ: VRTX) are unstoppable stocks to buy in 2025. David Jagielski (Eli Lilly): It may look as though Eli Lilly's stock has peaked given its recent slide, but there's still a lot more room for it to run higher.
First Week of March 21st Options Trading For Vertex Pharmaceuticals (VRTX)
HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is 'Grasping at Straws'
HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its gene-editing therapy for sickle cell disease.
Vertex's Pain Drug: Big Pharma's Next Major Success?
Vertex Pharmaceuticals' innovative pain drug holds significant potential, positioning the company for substantial growth in the expanding market.
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025
Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space.
Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
/PRNewswire/ -- Orna Therapeutics (through its wholly owned subsidiary ReNAgade Therapeutics Inc.) announced a three-year strategic research collaboration with...
Interesting VRTX Put And Call Options For February 2025
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
Santa Claus will soon be on his way delivering presents to kids around the world. Three Motley Fool contributors think they've identified fantastic stocks that could be in a good position to benefit from a Santa Claus rally. Here's why they chose AbbVie (NYSE: ABBV), Novo Nordisk (NYSE: NVO), and Vertex Pharmaceuticals (NASDAQ: VRTX).
Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock
The FDA signed off on Vertex's newest cystic fibrosis treatment. But it might not help beleaguered Vertex stock.
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
